iBio develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. iBio’s mission is to decrease drug failures, shorten drug development timelines, and open up new frontiers against the most promising targets. For more information, visit www.ibioinc.com.
Company Profile
Latest Presentation
Industry Classifications
Sector:
Healthcare
Industry:
Biotechnology
NAICS:
Pharmaceutical Preparation Manufacturing (325412)
SIC:
Pharmaceutical Preparations (2834)
Contact Information
Investor Relations
Stephen Kilmer
T: 646-274-3580
skilmer@ibioinc.com
Company Contact
iBio Inc.
8800 HSC Pkwy
Bryan, TX 77807
T: 979-446-0027
ir@ibioinc.com